NASDAQ:CMPX Compass Therapeutics Q4 2025 Earnings Report $2.38 +0.07 (+2.81%) As of 01:44 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Compass Therapeutics EPS ResultsActual EPS-$0.09Consensus EPS -$0.10Beat/MissBeat by +$0.01One Year Ago EPSN/ACompass Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue($0.90) millionBeat/MissN/AYoY Revenue GrowthN/ACompass Therapeutics Announcement DetailsQuarterQ4 2025Date3/5/2026TimeBefore Market OpensConference Call DateThursday, March 5, 2026Conference Call Time7:30AM ETUpcoming EarningsCompass Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Annual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K)Annual report Compass Therapeutics Earnings HeadlinesCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 15 at 2:15 AM | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) Price Target Raised to $6.00August 10, 2026 | americanbankingnews.comGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent highs. Margins as high as 75 percent make this the most profitable stretch in their history. Yet junior gold miners, the prime buyout targets for these cash-rich majors, are still priced as if gold were stuck at 1800 dollars an ounce instead of today's levels. Analyst Garrett Goggin calls this the Golden Anomaly, a gap he says rarely lasts long once a gold bull market gets going.August 18 at 1:00 AM | Golden Portfolio (Ad)Research Analysts Offer Predictions for CMPX Q3 EarningsAugust 10, 2026 | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) Rating Lowered to "Strong Sell" at Wall Street ZenAugust 8, 2026 | americanbankingnews.comCompass Therapeutics Reports Q2 2026 Results, Advances Tovecimig FDA Plans and Broadens Oncology PipelineAugust 6, 2026 | quiverquant.comQSee More Compass Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email. Email Address About Compass TherapeuticsCompass Therapeutics (NASDAQ:CMPX) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment. The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells. Both assets have advanced into clinical development, with ongoing studies evaluating safety, pharmacodynamics and preliminary efficacy across multiple tumor types. Compass also maintains a rich preclinical pipeline of next‐generation antibody constructs designed to address checkpoint resistance and immune suppression in solid tumors. Compass Therapeutics employs an integrated discovery and development model, combining in‐house antibody engineering capabilities with translational science and biomarker analysis. The company collaborates with academic institutions and contract research organizations to streamline the advancement of its molecules from lead optimization through early‐phase clinical trials. This approach supports rapid iteration and selection of candidates with differentiated mechanisms of action. Founded in 2018, Compass Therapeutics is led by President and Chief Executive Officer Ravi Mohan, Ph.D., whose experience spans immuno-engineering and oncology drug development. While primarily focused on the U.S. market, the company is positioned to pursue global clinical collaborations and strategic partnerships as its clinical programs mature.View Compass Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Home Depot Analysts See a Path to $375 and BeyondRTX Stock Gets a Radar Lock on a $23B Navy WinA Star Investor Just Trimmed Amazon—Here's What It meansFabrinet’s Sell-Off May Prove It Is One of AI’s Most Misunderstood StocksWendy’s Deal Buzz May Give Fast-Food Investors a New Reason to LookMichael Burry Is Betting Against Palantir Again—Should Investors Care?Uncle Sam’s Chip Trick: How the Government Built a Silicon Moat Upcoming Earnings Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
